Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2007 Dec;56(12):1770-98.
doi: 10.1136/gut.2007.119446. Epub 2007 May 8.

Guidelines on the irritable bowel syndrome: mechanisms and practical management

R Spiller  1 , Q Aziz, F Creed, A Emmanuel, L Houghton, P Hungin, R Jones, D Kumar, G Rubin, N Trudgill, P Whorwell; Clinical Services Committee of The British Society of Gastroenterology
Affiliations
Review

Guidelines on the irritable bowel syndrome: mechanisms and practical management

R Spiller et al. Gut. 2007 Dec.

Erratum in

  • Gut. 2008 Dec;57(12):1743

Abstract

Background: IBS affects 5-11% of the population of most countries. Prevalence peaks in the third and fourth decades, with a female predominance.

Aim: To provide a guide for the assessment and management of adult patients with irritable bowel syndrome.

Methods: Members of the Clinical Services Committee of The British Society of Gastroenterology were allocated particular areas to produce review documents. Literature searching included systematic searches using electronic databases such as Pubmed, EMBASE, MEDLINE, Web of Science, and Cochrane databases and extensive personal reference databases.

Results: Patients can usefully be classified by predominant bowel habit. Few investigations are needed except when diarrhoea is a prominent feature. Alarm features may warrant further investigation. Adverse psychological features and somatisation are often present. Ascertaining the patients' concerns and explaining symptoms in simple terms improves outcome. IBS is a heterogeneous condition with a range of treatments, each of which benefits a small proportion of patients. Treatment of associated anxiety and depression often improves bowel and other symptoms. Randomised placebo controlled trials show benefit as follows: cognitive behavioural therapy and psychodynamic interpersonal therapy improve coping; hypnotherapy benefits global symptoms in otherwise refractory patients; antispasmodics and tricyclic antidepressants improve pain; ispaghula improves pain and bowel habit; 5-HT(3) antagonists improve global symptoms, diarrhoea, and pain but may rarely cause unexplained colitis; 5-HT(4) agonists improve global symptoms, constipation, and bloating; selective serotonin reuptake inhibitors improve global symptoms.

Conclusions: Better ways of identifying which patients will respond to specific treatments are urgently needed.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest: Professor Aziz has received remuneration for consultancy advice to Novartis and Mundi Pharma, and has received research funding from GlaxoSmithKline (GSK) and Pfizer Pharmaceuticals. Professor Creed has received remuneration for consultancy advice to Eli Lilley and Company. Dr Emmanuel has been reimbursed for travelling and conferences by GSK and Novartis and has received research funding from GSK. Dr Houghton has received remuneration for advice and speaking (Novartis, Solvay, Clasado), together with financial support for the conduct of physiological research from Novartis, GSK, and Pfizer. Professor Hungin has received remuneration for speaking and consulting from GSK, Novartis, and AstraZeneca, and research funding from Novartis. Professor Jones has received remuneration for speaking and consulting from Novartis, Solvay, Astra‐Zeneca, and GSK. Professor Rubin has received remuneration for consultancy advice to Novartis and Tillots Pharma, and has received research funding from Novartis. He has shares in GSK. Professor Spiller has received remuneration for consultancy advice and received research support from Novartis Pharmaceuticals and GSK. He has also acted on an advisory board for Solvay Pharmaceuticals. Dr Trudgill has received remuneration for consultancy advice to Astra‐Zeneca and Ferring. Professor Whorwell has received remuneration for advice and his department has received financial support from Novartis, GSK, Pfizer, Solvay, Rotta Research, Proctor and Gamble, Astellas, and Tillots.

References

    1. Atkins D, Best D, Briss P A.et al Grading quality of evidence and strength of recommendations. BMJ 20043281490 - PMC - PubMed
    1. Andrews E B, Eaton S C, Hollis K A.et al Prevalence and demographics of irritable bowel syndrome: results from a large web‐based survey. Aliment Pharmacol Ther 200522935–942. - PubMed
    1. Dean B B, Aguilar D, Barghout V.et al Impairment in work productivity and health‐related quality of life in patients with IBS. Am J Manag Care 200511S17–S26. - PubMed
    1. Longstreth G F, Bolus R, Naliboff B.et al Impact of irritable bowel syndrome on patients' lives: development and psychometric documentation of a disease‐specific measure for use in clinical trials. Eur J Gastroenterol Hepatol 200517411–420. - PubMed
    1. Chang L. Epidemiology and quality of life in functional gastrointestinal disorders. Aliment Pharmacol Ther 200420(suppl 7)31–39. - PubMed